K

Knight Therapeutics Inc
TSX:GUD

Watchlist Manager
Knight Therapeutics Inc
TSX:GUD
Watchlist
Price: 5.29 CAD -0.19% Market Closed
Market Cap: 534.2m CAD
Have any thoughts about
Knight Therapeutics Inc?
Write Note

Knight Therapeutics Inc
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Knight Therapeutics Inc
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
K
Knight Therapeutics Inc
TSX:GUD
Long-Term Debt
CA$36.5m
CAGR 3-Years
138%
CAGR 5-Years
121%
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Long-Term Debt
$21.1B
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
3%
Sundial Growers Inc
NASDAQ:SNDL
Long-Term Debt
CA$136.5m
CAGR 3-Years
415%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Long-Term Debt
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Long-Term Debt
$24.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Curaleaf Holdings Inc
CNSX:CURA
Long-Term Debt
$884.9m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Knight Therapeutics Inc
Glance View

Market Cap
534.2m CAD
Industry
Pharmaceuticals

Knight Therapeutics Inc engages in acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. The company is headquartered in Montreal, Quebec and currently employs 660 full-time employees. The company went IPO on 2014-02-28. The firm's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. The Company’s products include BIJUVA Estradiol and Progesterone capsule, IMVEXXY Estradiol vaginal inserts, IBSRELA Tenapanor tablets, TRELSTAR Prostate Triptorelin, TRELSTAR Endometriosis Triptorelin, ILUVIEN Fluocinolone acetonide, Nerlynx Neratinib Tablets, Nerlynx Patient Checklist, Nerlynx Prescriber Checklist, Burinex Bumetanide, Probuphine Buprenorphine implant, Movantik Naloxegol and Neuragen. The company owns Biotoscana Investments S.A., a pan-Latin American specialty pharmaceutical company. Its subsidiaries operates under United Medical, Biotoscana Farma and Laboratorio LKM.

GUD Intrinsic Value
6.31 CAD
Undervaluation 16%
Intrinsic Value
Price
K

See Also

What is Knight Therapeutics Inc's Long-Term Debt?
Long-Term Debt
36.5m CAD

Based on the financial report for Sep 30, 2024, Knight Therapeutics Inc's Long-Term Debt amounts to 36.5m CAD.

What is Knight Therapeutics Inc's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
121%

Over the last year, the Long-Term Debt growth was -33%. The average annual Long-Term Debt growth rates for Knight Therapeutics Inc have been 138% over the past three years , 121% over the past five years .

Back to Top